Combined gastric and ileocecal toxicity (serpiginous ulcers) after oral Kayexalate in sorbital therapy

Prabir Roy-Chaudhury, Ira S. Meisels, Steven Freedman, Theodore I. Steinman, Michael Steer

Research output: Contribution to journalArticlepeer-review

28 Scopus citations

Abstract

Kayexalate (Roxane Labs, Columbus, OH) in sorbitol is commonly administered by the oral and rectal route for the treatment of hyperkalemia in patients with renal failure. It is believed to have minimal toxicity because it functions as a cation exchanger and is not absorbed. We herein report on a patient who developed identical serpiginous ulcers in the stomach and the terminal ileum after the use of Kayexalate. We believe that this drug could have significant gastrointestinal toxicity in specific patient groups and suggest tentative guidelines, both for the identification of such patients and for the safer use of Kayexalate in these circumstances.

Original languageEnglish
Pages (from-to)120-122
Number of pages3
JournalAmerican Journal of Kidney Diseases
Volume30
Issue number1
DOIs
StatePublished - Jul 1997
Externally publishedYes

Keywords

  • Gastric
  • Ileocecal
  • Kayexalate
  • Ulcers

Fingerprint

Dive into the research topics of 'Combined gastric and ileocecal toxicity (serpiginous ulcers) after oral Kayexalate in sorbital therapy'. Together they form a unique fingerprint.

Cite this